Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients
1 other identifier
observational
50
0 countries
N/A
Brief Summary
The aim of this study is to evaluate the role of miRNA 125a -5p and miRNA143-3p as a non invasive biomarker in diagnosis of breast cancer and the relationship between MiRNA expression and histopathological features as tumor stage ,grade ,molecular subtypes. Also trying to correlate the results with MRI radiological findings which may help in better selection of treatment protocols.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 25, 2021
CompletedFirst Posted
Study publicly available on registry
March 2, 2021
CompletedStudy Start
First participant enrolled
March 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2024
CompletedMarch 8, 2021
March 1, 2021
1 year
February 25, 2021
March 4, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
assessment of the value of MiRNA in diagnosis and prognosis of breast cancer patients
To evaluate diagnostic and prognostic role of MiRNA 125a-5p and 143-3p as a non invasive biomarker in breast cancer
18-24 month
correlat MiRNA expression with MRI findings for better selection of treatment plan and out come
Also trying to correlate the results with MRI radiological findings which may help in better selection of treatment protocols.
18-24 months
Study Arms (2)
first group (control group)
25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
Second group (breast cancer patient group)
25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
Interventions
blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
Eligibility Criteria
females 18 years old or above
You may qualify if:
- control group of normal healthy individuals who don't have tumors in other organs.
- breast cancer group Patients with confirmed breast cancer who didn't receive radiotherapy ,chemotherapy ,hormonal therapy or surgical treatment.
You may not qualify if:
- Patients refuse to be part of study and undergo examination .
- All patients with breast cancer that had received chemotherapy, radiotherapy , ,hormonal or surgical treatment.
- History of benign or malignant tumors in other organs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
PMID: 30207593BACKGROUND
Biospecimen
blood sample by veinpuncture prosedure into EDITA tubes
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- demonstrator
Study Record Dates
First Submitted
February 25, 2021
First Posted
March 2, 2021
Study Start
March 1, 2022
Primary Completion
March 1, 2023
Study Completion
March 1, 2024
Last Updated
March 8, 2021
Record last verified: 2021-03